REG - Oxford Biomedica PLC - Block listing Application <Origin Href="QuoteRef">OXB.L</Origin>

Oxford BioMedicaAnnouncement

06/09/2014 20:37

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20140725:nRSY3332Na


RNS Number : 3332N
Oxford Biomedica PLC
25 July 2014 
 
Block listing Application 
 
Oxford, UK - 25 July 2014: Oxford BioMedica plc (LSE: OXB), ("OXB" or "the
Company") a leading gene- and cell-therapy company, announces that
applications have been made to the Financial Conduct Authority and the London
Stock Exchange for admission to (i) the Premium segment of the Official List
and (ii) to trading on the London Stock Exchange's markets for a block listing
of securities totalling 15 million ordinary shares of 1 pence each (the
"Ordinary Shares"). 
 
The Ordinary Shares are being reserved under a block listing and will be
issued from time to time pursuant to the following schemes: 
 
·     OXB Share Option Scheme (10 million Ordinary Shares); and 
 
·     LTIP (5 million Ordinary Shares). 
 
It is expected that admission of the Ordinary Shares will become effective on
28 July 2014. The Ordinary Shares will rank pari passu in all respects with
the Company's existing ordinary shares in issue. 
 
-Ends- 
 
 For further information, please contact:                                                                                  
 Oxford BioMedica plc:John Dawson, Chief Executive OfficerTim Watts, Chief Financial Officer     Tel: +44 (0)1865 783 000  
 Media Enquiries:Mary-Jane Elliott/Emma Thompson/Matthew NealConsilium Strategic Communications  Tel: +44 (0)20 3709 5700  
                                                                                                                           
 
 
Notes for editors 
 
About Oxford BioMedica® 
 
Oxford BioMedica plc (LSE: OXB) is a biopharmaceutical company developing
innovative gene-based medicines and therapeutic vaccines that aim to improve
the lives of patients with high unmet medical needs. The Company's technology
platform includes a highly efficient LentiVector® gene delivery system, which
has specific advantages for targeting diseases of the central nervous system
and the eye; and a unique tumour antigen (5T4), which is an ideal target for
anti-cancer therapy.  Through in-house and collaborative research, Oxford
BioMedica has a broad range of partners and licensees including Sanofi,
Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec,
Emergent BioSolutions, ImaginAb and Immune Design Corp. Further information is
available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk. 
 
This information is provided by RNS
The company news service from the London Stock Exchange